Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Barclays Keeps Their Buy Rating on Viatris (VTRS)

Tipranks - Tipranks - Tue Apr 14, 4:26AM CDT

In a report released today, Glen Santangelo from Barclays maintained a Buy rating on Viatris, with a price target of $17.00.

Claim 30% Off TipRanks

Santangelo covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Henry Schein, and McKesson. According to TipRanks, Santangelo has an average return of 4.7% and a 50.18% success rate on recommended stocks.

Currently, the analyst consensus on Viatris is a Moderate Buy with an average price target of $15.25.

See Insiders’ Hot Stocks on TipRanks >>

Based on Viatris’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.7 billion and a GAAP net loss of $340.1 million. In comparison, last year the company earned a revenue of $3.53 billion and had a GAAP net loss of $516.5 million

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is neutral on the stock. Last month, Paul Campbell, the Chief Accounting Officer and Corporate Controller of VTRS sold 21,350.00 shares for a total of $283,528.00.

Read More on VTRS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).